Intracranial hemorrhages associated with intravenous platelet glycoprotein IIB/IIIA receptor inhibitors in the United States

Adnan I. Qureshi; M. S. Hussain; Abu Nasar; Jawad F. Kirmani; Afshin A. Divani; Shafiudin Ahmed; M. Fareed K. Suri

doi:10.1007/s10557-005-4390-3

Intracranial hemorrhages associated with intravenous platelet glycoprotein IIB/IIIA receptor inhibitors in the United States

Adnan I. Qureshi, M. S. Hussain, Abu Nasar, Jawad F. Kirmani, Afshin A. Divani, Shafiudin Ahmed, M. Fareed K. Suri

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Objectives: To determine the rates of intracranial hemorrhages associated with GP IIb/IIIa inhibitors in routine practice. Background: Rates of intracranial hemorrhages (ICH) among patients treated with platelet glycoprotein (GP) IIb/IIIa inhibitors for coronary interventions and acute coronary syndromes have been studied within clinical trials but not in routine practice. Methods: We evaluated the rates of ICH in routine practice in United States (US) using national estimates of rates, in-hospital outcomes, and mortality obtained from National Hospital Discharge Survey. Results: There were 367 294 patients aged 18 years or greater who were treated with platelet GP IIb/IIIa inhibitors between 2000 and 2002 in United States. ICH was observed in 479 (0.13%) of the 367 294 patients with a 100% associated mortality. ICHs related to GP IIb/IIIa inhibitors comprised 0.12% of the total number of ICHs (n = 411 621) observed in United States between 2000 and 2002. Conclusions: ICH related to platelet GPIIb/IIIa inhibitors is uncommon but associated with high mortality.

Original language	English (US)
Pages (from-to)	371-373
Number of pages	3
Journal	Cardiovascular Drugs and Therapy
Volume	19
Issue number	5
DOIs	https://doi.org/10.1007/s10557-005-4390-3
State	Published - Oct 2005
Externally published	Yes

Keywords

Abciximab
Eptifibatide
National estimates
National survey
Tirofiban hydrochloride

Access

10.1007/s10557-005-4390-3

OpenUrl availability

Full text

Cite this

@article{651122f9d0e6466f930b2e21f332964e,

title = "Intracranial hemorrhages associated with intravenous platelet glycoprotein IIB/IIIA receptor inhibitors in the United States",

abstract = "Objectives: To determine the rates of intracranial hemorrhages associated with GP IIb/IIIa inhibitors in routine practice. Background: Rates of intracranial hemorrhages (ICH) among patients treated with platelet glycoprotein (GP) IIb/IIIa inhibitors for coronary interventions and acute coronary syndromes have been studied within clinical trials but not in routine practice. Methods: We evaluated the rates of ICH in routine practice in United States (US) using national estimates of rates, in-hospital outcomes, and mortality obtained from National Hospital Discharge Survey. Results: There were 367 294 patients aged 18 years or greater who were treated with platelet GP IIb/IIIa inhibitors between 2000 and 2002 in United States. ICH was observed in 479 (0.13%) of the 367 294 patients with a 100% associated mortality. ICHs related to GP IIb/IIIa inhibitors comprised 0.12% of the total number of ICHs (n = 411 621) observed in United States between 2000 and 2002. Conclusions: ICH related to platelet GPIIb/IIIa inhibitors is uncommon but associated with high mortality.",

keywords = "Abciximab, Eptifibatide, National estimates, National survey, Tirofiban hydrochloride",

author = "Qureshi, {Adnan I.} and Hussain, {M. S.} and Abu Nasar and Kirmani, {Jawad F.} and Divani, {Afshin A.} and Shafiudin Ahmed and Suri, {M. Fareed K.}",

year = "2005",

month = oct,

doi = "10.1007/s10557-005-4390-3",

language = "English (US)",

volume = "19",

pages = "371--373",

journal = "Cardiovascular Drugs and Therapy",

issn = "0920-3206",

publisher = "Kluwer Academic Publishers",

number = "5",

}

TY - JOUR

T1 - Intracranial hemorrhages associated with intravenous platelet glycoprotein IIB/IIIA receptor inhibitors in the United States

AU - Qureshi, Adnan I.

AU - Hussain, M. S.

AU - Nasar, Abu

AU - Kirmani, Jawad F.

AU - Divani, Afshin A.

AU - Ahmed, Shafiudin

AU - Suri, M. Fareed K.

PY - 2005/10

Y1 - 2005/10

N2 - Objectives: To determine the rates of intracranial hemorrhages associated with GP IIb/IIIa inhibitors in routine practice. Background: Rates of intracranial hemorrhages (ICH) among patients treated with platelet glycoprotein (GP) IIb/IIIa inhibitors for coronary interventions and acute coronary syndromes have been studied within clinical trials but not in routine practice. Methods: We evaluated the rates of ICH in routine practice in United States (US) using national estimates of rates, in-hospital outcomes, and mortality obtained from National Hospital Discharge Survey. Results: There were 367 294 patients aged 18 years or greater who were treated with platelet GP IIb/IIIa inhibitors between 2000 and 2002 in United States. ICH was observed in 479 (0.13%) of the 367 294 patients with a 100% associated mortality. ICHs related to GP IIb/IIIa inhibitors comprised 0.12% of the total number of ICHs (n = 411 621) observed in United States between 2000 and 2002. Conclusions: ICH related to platelet GPIIb/IIIa inhibitors is uncommon but associated with high mortality.

AB - Objectives: To determine the rates of intracranial hemorrhages associated with GP IIb/IIIa inhibitors in routine practice. Background: Rates of intracranial hemorrhages (ICH) among patients treated with platelet glycoprotein (GP) IIb/IIIa inhibitors for coronary interventions and acute coronary syndromes have been studied within clinical trials but not in routine practice. Methods: We evaluated the rates of ICH in routine practice in United States (US) using national estimates of rates, in-hospital outcomes, and mortality obtained from National Hospital Discharge Survey. Results: There were 367 294 patients aged 18 years or greater who were treated with platelet GP IIb/IIIa inhibitors between 2000 and 2002 in United States. ICH was observed in 479 (0.13%) of the 367 294 patients with a 100% associated mortality. ICHs related to GP IIb/IIIa inhibitors comprised 0.12% of the total number of ICHs (n = 411 621) observed in United States between 2000 and 2002. Conclusions: ICH related to platelet GPIIb/IIIa inhibitors is uncommon but associated with high mortality.

KW - Abciximab

KW - Eptifibatide

KW - National estimates

KW - National survey

KW - Tirofiban hydrochloride

UR - http://www.scopus.com/inward/record.url?scp=29744442962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29744442962&partnerID=8YFLogxK

U2 - 10.1007/s10557-005-4390-3

DO - 10.1007/s10557-005-4390-3

M3 - Article

C2 - 16382300

AN - SCOPUS:29744442962

SN - 0920-3206

VL - 19

SP - 371

EP - 373

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

IS - 5

ER -

Intracranial hemorrhages associated with intravenous platelet glycoprotein IIB/IIIA receptor inhibitors in the United States

Abstract

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this